Member Info for Laura2022

See last week Bearded

It's really easy

Not at all NU

You thought it had no cash and was to be avoided but saw a great opportunity after 1p

I apologised for getting something wrong

Hopefully people will reciprocate

Also

After VAL news yesterday people buying PYC....

Newuncle

Reckon 100% here

Priced only at £3.5mln

USA huge market as per RNS on 14th

Oxford BioDynamics

("OBD" or the "Company" and, together with its subsidiaries, the "Group")

EpiSwitch® CiRT Receives Clinical Approval from

New York State Clinical Laboratory Evaluation Program (NYS CLEP)

Oxford, UK - 22 October 2024 - Oxford BioDynamics, Plc (AIM: OBD, the Company), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on OBD's EpiSwitch® 3D genomics platform, and its partner NEXT Molecular Analytics (VA, USA) have been informed of New York State Clinical Laboratory Evaluation Program's (NYS CLEP) approval of the EpiSwitch® CiRT

Lovely...

As is your perogative NU - gluck either way

Charts very very oversold at 1p to 1.10p

20 Oct 2024 11:29

Since 14th Oct RNS ( 2 weeks ago) only Lonbard have trimmed...going 5% to 4.99%, it seems.....at least for now.....the others are support9ng the strategic review

Vulpes Investment Management 9.51

Arbuthnot Latham (Nominees)* 9.13

Unicorn Asset Management 8.06

Lombard Odier Asset Management 4.99

Seneca Partners* 4.93

Investec Wealth & Investment* 4.99

Top investors 41.61

Other shareholders 58.39

Total shareholders 100.00

Source: Oxford BioDynamics Note: as of 15/10/24 * as last notified to Oxford BioDynamics

From Trench123

23 mins : PS discusses the slide headed 'Immediate Growth Levers - Growth and Profit' and mentions that 'many of you will have seen this slide before as I have used it in a number of other presentations'. Firstly good to see the word 'Profit' mentioned, but secondly , I do not recall seeing this slide before, but I may well be mistaken. It could have been used to attract potential investors for the last funding round (it could also conceivably have been in presentations to potential future buyers/partners/long term investors)

26 mins & 32 mins : Much on the development and projected commercialisation of the personalised dosing tool through its partnership with DosemeRx. PS mentions mentions that he is 'conscious that we need to extract value from this tool'. He also notes we 'also intend to explore other avenues for this tool'. Looks like this is all progressing very well and could be transformative for PYC

27 mins/30 mins : Head of Modelling will be 'an expert in the field of modelling and simulation with broad networks across the industry'. Scheduled to start in November

29 mins : With reference to Biostatistics PS mentions ' We are exploring strategic options to enable accelerated growth' . 'This is something we are very much actively exploring at the moment'

31 mins : Scientific publications. 'Progressing a number of scientific papers at the moment' . 'Two have been submitted back to the respective journals and one is about to be submitted' PS mentions 'being able to credentialise your technical skills through peer reviews in scientific journals is a very important and very useful marketing tool for us'.

'Hopefully we can announce their publication very soon'

33 mins : PREDICT-ONC Trial at Blackpool Hospital 'going through final stages of ethical and regulatory approval'. 'We hope to announce the official start of the trial very soon' I though this would have been a little further advanced, but will presumably result in more of the Innovate grant income being reflected in the current financial year'. The end date of the trial remains unchanged

PS is highly organised and motivated and is building a very strong team to drive sustainable growth. I like what I see

Amd...as per the VAL presentation a decision soon on VAL201 licencing which would trigger up to £6mln to PYC (lots of caveats of course)

Amd huge client list

Thanks toffee for that explanation

Facts , as Mozak says are PYC are £1.4mln yet

Record revenues won 2023/24

Record revenues booked 2024 already for H2

Cash of £600k or so after recent fund raise

A very good recent webinar ( see Trench123 notes)

Personalised dosing app nearing commercialisation (see King Homer posts)

Mozak/toffee

Not sure where false analysis has been shown but welcome aboard anyway

Well done NU if you called correctly

Have u bought ?

Coming

Intimidation of Executives

Since these recent developments, the board members have faced serious intimidation, including threats of violence to their homes and families, aimed at destabilising the Company. These threats, originating from individuals in Europe, are unacceptable for anyone doing their very best in difficult circumstance and have been reported in detail to the Federal Police in multiple countries, where investigations are underway.

This situation has created significant safety concerns, disrupting normal operations and potentially impacting the Company's ability to make critical decisions

Someone on TG says OBD is SETS platform

What does that means please ?

All the 0 65 and 66 were buys debull

Similar to yesterday

The VAL rise was due to an excellent presentation from VAL CEO and he said decision/closure on VAL201 merger with EUDA/THX shortly

EUDA raised $100mln last week which suggest merger close which allows the completion of VAL201 and monetisation for VAL and therfore PYC

Pj66

Uncanny will squirm now ...just like the naughty piglet

Uncanny over last 12mths been found lying so many time

So you wee there ...as a non shareholder..but didn't post after the event like Bladster etc

We can see through you